Yantai Dongcheng Pharmaceutical Co Ltd (SHE:002675) — Market Cap & Net Worth
Market Cap & Net Worth: Yantai Dongcheng Pharmaceutical Co Ltd (002675)
Yantai Dongcheng Pharmaceutical Co Ltd (SHE:002675) has a market capitalization of $1.57 Billion (CN¥10.71 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #7207 globally and #1701 in its home market, demonstrating a -6.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yantai Dongcheng Pharmaceutical Co Ltd's stock price CN¥12.99 by its total outstanding shares 824595705 (824.60 Million). Analyse 002675 cash generation efficiency to see how efficiently the company converts income to cash.
Yantai Dongcheng Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Yantai Dongcheng Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.10 Billion to $1.57 Billion (-0.74% CAGR).
Yantai Dongcheng Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yantai Dongcheng Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.51x
Yantai Dongcheng Pharmaceutical Co Ltd's market cap is 0.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.02x
Yantai Dongcheng Pharmaceutical Co Ltd's market cap is 8.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.10 Billion | $794.92 Million | $89.75 Million | 2.64x | 23.39x |
| 2016 | $1.61 Billion | $1.16 Billion | $130.95 Million | 1.39x | 12.31x |
| 2017 | $1.33 Billion | $1.60 Billion | $172.63 Million | 0.84x | 7.72x |
| 2018 | $891.93 Million | $2.33 Billion | $280.43 Million | 0.38x | 3.18x |
| 2019 | $1.83 Billion | $2.99 Billion | $154.71 Million | 0.61x | 11.85x |
| 2020 | $2.30 Billion | $3.42 Billion | $417.77 Million | 0.67x | 5.50x |
| 2021 | $1.84 Billion | $3.91 Billion | $151.56 Million | 0.47x | 12.16x |
| 2022 | $1.96 Billion | $3.58 Billion | $307.29 Million | 0.55x | 6.37x |
| 2023 | $2.19 Billion | $3.28 Billion | $209.74 Million | 0.67x | 10.44x |
| 2024 | $1.47 Billion | $2.87 Billion | $183.83 Million | 0.51x | 8.02x |
Competitor Companies of 002675 by Market Capitalization
Companies near Yantai Dongcheng Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Yantai Dongcheng Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Yantai Dongcheng Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yantai Dongcheng Pharmaceutical Co Ltd's market cap moved from $2.10 Billion to $ 1.57 Billion, with a yearly change of -0.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.57 Billion | -5.46% |
| 2025 | CN¥1.66 Billion | +12.44% |
| 2024 | CN¥1.47 Billion | -32.68% |
| 2023 | CN¥2.19 Billion | +11.87% |
| 2022 | CN¥1.96 Billion | +6.26% |
| 2021 | CN¥1.84 Billion | -19.77% |
| 2020 | CN¥2.30 Billion | +25.25% |
| 2019 | CN¥1.83 Billion | +105.58% |
| 2018 | CN¥891.93 Million | -33.10% |
| 2017 | CN¥1.33 Billion | -17.32% |
| 2016 | CN¥1.61 Billion | -23.20% |
| 2015 | CN¥2.10 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Yantai Dongcheng Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.57 Billion USD |
| MoneyControl | $1.57 Billion USD |
| MarketWatch | $1.57 Billion USD |
| marketcap.company | $1.57 Billion USD |
| Reuters | $1.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Yantai Dongcheng Pharmaceutical Co Ltd
Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluro… Read more